2020 Annual Report on Form 10-K Are Available At

Total Page:16

File Type:pdf, Size:1020Kb

2020 Annual Report on Form 10-K Are Available At TOTAL REVENUES NON-GAAP ADJUSTED NET NET CASH PROVIDED BY $ in millions INCOME PER DILUTED SHARE1,2 OPERATING ACTIVITIES (audited) (unaudited) $ in millions (unaudited) $2,364 $900 $2,162 $799 $1,891 $776 $15.38 $693 $1,619 $13.54 $12.46 $9.59 2017 2018 2019 2020 2017 2018 2019 2020 2017 2018 2019 2020 13.4% 3 YEAR CAGR 9.1% 3 YEAR CAGR 9.1% 3 YEAR CAGR NOTICE OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 29, 2021 Dear Shareholder: Whether or not you expect to The 2021 annual general meeting of shareholders (the “annual meeting”) of Jazz attend the meeting, please vote as Pharmaceuticals plc, a public limited company formed under the laws of Ireland (the “company”), soon as possible. You may vote will be held on Thursday, July 29, 2021, at 3:00 p.m. local time at our corporate headquarters your shares: Proxy located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland, for the following purposes: 1. To elect by separate resolutions each of the four nominees for director named in the Over the Telephone accompanying proxy statement (the “proxy statement”) to hold office until the 2024 annual 1-800-690-6903 meeting of shareholders (Proposal 1). Via the Internet 2. To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin, or KPMG, as www.proxyvote.com the independent auditors of the company for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the independent auditors’ remuneration (Proposal 2). By Mail Complete, sign and 3. To approve, on a non-binding advisory basis, the compensation of the company’s named return proxy card executive officers, or NEOs, as disclosed in the accompanying proxy statement (Proposal 3). In Person 4. To renew the board of directors’ existing authority under Irish law to allot and issue ordinary Attend Annual Meeting shares (Proposal 4). 5. To renew the board of directors’ existing authority under Irish law to allot and issue ordinary If you received a proxy card or shares for cash without first offering those ordinary shares to existing shareholders pursuant voting instruction card by mail, you to the statutory pre-emption right that would otherwise apply (Proposal 5). may submit your proxy card or voting instruction card mailing your 6. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to proxy card or voting instruction another time and place to solicit additional proxies if there are insufficient votes at the time of card in the envelope provided. the annual meeting to approve Proposal 5 (Proposal 6). Proxy cards must be received by To conduct any other business properly brought before the annual meeting. July 28, 2021. Electronic proxy cards submitted via the internet or Proposals 1, 2, 3, 4 and 6 are ordinary resolutions, requiring the affirmative vote of a majority of by telephone must be received by the votes cast (in person or by proxy) at the annual meeting. Proposal 5 is a special resolution, 11:59 p.m., U.S. Eastern Time, on requiring the approval of not less than 75% of the votes cast (in person or by proxy) at the annual July 28, 2021. It may not be meeting. possible to count proxy cards received after the relevant time In addition to the above proposals, the annual meeting will also receive and consider the towards voting. Proxy cards company’s Irish statutory financial statements for the fiscal year ended December 31, 2020 and received will be forwarded to the the reports of the directors and auditors thereon. There is no requirement under Irish law that the company’s registered office Irish statutory financial statements be approved by the shareholders, and no such approval will be electronically before sought at the annual meeting. Under the company’s Memorandum and Articles of Association commencement of the annual (our “articles”), and the Irish Companies Act 2014 (the “2014 Act”), Proposals 1 and 2 are deemed meeting to comply with Irish law. to be ordinary business, and Proposals 3, 4, 5 and 6 are deemed to be special business. Even if you have voted by proxy, The record date for the annual meeting is June 2, 2021. Only shareholders of record at the close you may still vote in person if you of business on that date may vote at the annual meeting or any adjournment or postponement attend the meeting. Please note, thereof. however, that if the record holder of your ordinary shares is a broker, A shareholder entitled to attend and vote at the annual meeting is entitled to appoint one or more bank or other agent, and you wish proxies to attend, speak and vote instead of him or her at the annual meeting, using the proxy to vote at the meeting, you must card provided (or the form of proxy contained in section 184 of the 2014 Act) or using an obtain a proxy issued in your name electronic proxy card by telephone or via the internet in the manner described in this proxy from that record holder. statement. A proxy need not be a shareholder of record. Important Notice Regarding the Availability of Proxy Materials for the annual meeting of shareholders to be held on July 29, 2021, at 3:00 p.m. local time at our corporate headquarters located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. The proxy statement, our letter to shareholders and our 2020 Annual Report on Form 10-K are available at https://materials.proxyvote.com/G50871. By order of the board of directors, /s/ Aislinn Doody Aislinn Doody, Company Secretary Dublin, Ireland June 11, 2021 Potential Impacts of the COVID-19 Pandemic on the Annual General Meeting In light of the ongoing COVID-19 pandemic, the company would like to emphasize that we consider the health of our shareholders, employees and other attendees a top priority. We are monitoring guidance issued by appropriate governmental health agencies, including the Irish Health Service Executive, or the HSE, the Irish government, the U.S. Center for Disease Control and Prevention and the World Health Organization, collectively, the Health Authorities, and we have implemented, and will continue to implement the measures advised by the relevant Health Authorities to minimize the spread of COVID-19. Information on such measures and on COVID-19 generally is available on the HSE’s website at https://www.hse.ie/eng/ services/news/newsfeatures/covid19-updates/. The annual meeting will be held in accordance with HSE and relevant Health Authority guidance. Should we determine that alternative arrangements are necessitated due to public health recommendations regarding containment of COVID-19, which may include a change in date or time of the meeting, a change in venue or format of the meeting we will announce our decision by press release and/or filing with the Securities Exchange Commission as additional soliciting materials and also post information on the investor relations page of the company’s website found at https://investor.jazzpharma.com/news. We encourage shareholders to keep up-to-date with, and follow the guidance from the Government of Ireland and the Department of Health (of Ireland) (as appropriate), as circumstances may change at short notice. Due to this uncertainty, shareholders are strongly encouraged to vote their shares by proxy in advance at the annual meeting. TABLE OF CONTENTS PROXY OVERVIEW 1 PROPOSAL 2 RATIFY, ON A NON-BINDING ADVISORY BASIS, THE APPOINTMENT OF Business Overview ............................... 1 Information About our Board of Directors .............. 3 INDEPENDENT AUDITORS AND AUTHORIZE, Shareholder and Other Stakeholder Engagement ...... 5 IN A BINDING VOTE, THE BOARD OF ESG Highlights ................................... 7 DIRECTORS, ACTING THROUGH THE AUDIT Summary of Shareholder Voting Matters and Board COMMITTEE, TO DETERMINE THE Recommendations ................................13 INDEPENDENT AUDITORS’ REMUNERATION 92 GENERAL 18 Independent Registered Public Accounting Firm Fees and Services .................................... 92 CORPORATE GOVERNANCE AND BOARD Pre-Approval Policies and Procedures .............. 93 Proxy MATTERS 19 Independence .................................. 93 Overview ........................................19 PROPOSAL 3 NON-BINDING ADVISORY VOTE Independence of the Board of Directors ..............19 ON EXECUTIVE COMPENSATION 94 Board Leadership Structure and Risk Oversight ........19 Meetings of the Board of Directors ...................21 PROPOSAL 4 RENEW DIRECTORS’ Director Commitments .............................21 AUTHORITY TO ISSUE SHARES 102 Classified Board Structure ..........................21 Information About Board Committees ................21 PROPOSAL 5 RENEW DIRECTORS’ Audit Committee ..................................22 AUTHORITY TO ISSUE SHARES FOR CASH Report of the Audit Committee of the Board of WITHOUT FIRST OFFERING SHARES TO Directors ........................................24 EXISTING SHAREHOLDERS 103 Compensation Committee ..........................24 Compensation Committee Processes and Procedures . 25 Compensation Committee Interlocks and Insider PROPOSAL 6 ADJOURNMENT PROPOSAL 105 Participation .....................................26 Compensation Consultant Fees .....................26 QUESTIONS AND ANSWERS ABOUT THESE Compensation Committee Report ...................27 PROXY MATERIALS AND VOTING 106 Nominating and Corporate Governance Committee .....27 Corporate Governance Strengths ....................29 OTHER MATTERS 113 Other Corporate Governance Matters ................29
Recommended publications
  • Alkermes Public Limited Company
    ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements For the Year Ended March 31, 2013 ALKERMES PLC Table of Contents Page Directors’ Report .......................................................... 2 Statement of Directors’ Responsibilities .......................................... 56 Independent Auditors’ Report—Group ........................................... 57 Consolidated Profit and Loss Account ........................................... 59 Consolidated Statement of Comprehensive Income (Loss) ............................. 60 Consolidated Balance Sheet ................................................... 61 Consolidated Statement of Cash Flows ........................................... 63 Consolidated Reconciliation of Shareholders’ Funds ................................. 62 Notes to the Consolidated Financial Statements .................................... 64 Independent Auditors’ Report—Company ......................................... 111 Company Balance Sheet ..................................................... 113 Notes to the Company Financial Statements ....................................... 114 1 DIRECTORS’ REPORT For the Year Ended March 31, 2013 The directors present their report and audited consolidated financial statements for the fiscal year ended March 31, 2013. The directors have elected to prepare the consolidated financial statements in accordance with section 1 of the Companies (Miscellaneous Provisions) Act, 2009, which provides that a true and fair view of the state of
    [Show full text]
  • In Re: Alkermes Securities Litigation 03-CV-12091-Consolidated
    Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 1 of 49 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS In re ALKERMES SECURITIES ) Master Docket No. 03-CV-12091-RCL LITIGATION ) ) CLASS ACTION This Document Relates To: ) ) ALL ACTIONS. ) ) ) CONSOLIDATED COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 2 of 49 SUMMARY AND OVERVIEW 1. This is a securities class action on behalf of all purchasers of the common stock of Alkermes, Inc. (“Alkermes” or the “Company”) between April 22, 1999 and July 1, 2002 (the “Class Period”), against Alkermes and certain of its officers and directors for violations of the Securities Exchange Act of 1934 (the “Exchange Act”). 2. Alkermes is a biopharmaceutical company focused on the development of controlled- release drug delivery technologies and their application to existing or new drug therapies. Among the drug delivery technologies defendants seek to develop are sustained-release systems based on biodegradable polymeric microspheres, including those based on Medisorb polymers. 3. In 1996, Alkermes entered into an agreement with JPI Pharmaceutical International (“Janssen”), an affiliate of pharmaceutical giant Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“Johnson & Johnson”), to develop an injectable form of the schizophrenic drug Risperdal, based upon the Medisorb polymer technology, called Risperdal Consta. Janssen has marketed the oral form of Risperdal since 1993, with sales of $2.3 billion in 2003. According to a December 12, 2001 report by analysts Thomas Weisel Partners, LLC (“Thomas Weisel”), during the Class Period, oral Risperdal was the most prescribed drug in the $5.3 billion atypical antipsychotic market.
    [Show full text]
  • Explanation of Conflict of Interest Disclosure Parts: Part One: All
    Explanation of Conflict of Interest Disclosure Parts: Part One: All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2011-Present) Part Two: Income Sources & Equity of $10,000 or greater Part Three: Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2011-Present): Part Four: Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2011-Present) Part Five: My primary employer is a pharmaceutical/biotech/medical device company. 2012 Program Committee Disclosures Anissa Abi-Dargham: Part 1: Pfizer; Otsuka; Takeda; Sunovion; Shire; Roche; Pierre Favre; Part 2: Pierre Favre William Carlezon: Part 1: Referring to 2010-2011: Scientific Advisory Board, Myneurolab.com; Consultant, Concert Pharmaceuticals; Consultant, Lantheus Medical Imaging; Consultant, Transcept Pharmaceuticals, (Spouse) Senior Scientist, EMD Serono; Part 2: (Spouse) Senior Scientist, EMD Serono, Part 3: (Spouse) Senior Scientist, EMD Serono Cameron Carter: Part1: GlaxoSmithKline research; Part 4: GlaxoSmithKline Karl Deisseroth: Part
    [Show full text]
  • Final Attendee List
    Jennifer Abnet GlaxoSmithKline I GlaxoSmithKline I Jane Arboleda APRN Guardant I Molly Benson Sanjiv Agarwala MD Puma Biotechnology I Cancer Expert Now I Joe Arminger AbbVie I Seth Berkowitz LCSW, Manmeet Ahluwalia MD, CCLS MBA Patricia Armstrong The Leukemia & Lymphoma Miami Cancer Institute I Novartis I Society V Steve Albers Kim Arnold APRN CPNP Barry Berman MD, MS Alexion V CPHON Florida Cancer Specialists I Servier Pharmaceuticals I Maritza Alencar DNP, Tizano Bernard MBA, APRN, BMTCN Sheila Arrington MSN, Cancer Care Centers of Miami Cancer Institute V APRN, NP-C, AOCN Brevard I Puma Biotechnology I Carmen Allen MSIT Ana Mari Bernardini Pharmavoxx V Shannon Ashmon Novartis Oncology I Eisai, Inc I Luly Almeida Bernard Berry MBA Incyte Corporation I Sarah Ashton MS AstraZeneca Pharmaceuticals Guardant Health I I Talat Almukhtar MD Orlando Health Cancer Melissa Austin Jason Bever Institute I Cancer Care Centers of Oncopeptides I Brevard I Beatrice Alvarado Roberts Amy Bignon MD Garland Avera Doyle Caris Life Sciences I University of Florida I Jazz Pharmaceuticals I Nadeem Bilani MD Tadeu Ambros MD Francie Babcock Cleveland Clinic I FCS I AMAG Pharmaceuticals/Covis I Angela Bilik RN BSN Douglas Anderson AstraZeneca I Incyte Corporation I Craig Bailey Astra Zeneca I Jamie Bilsky BS Blesson Andrews Genentech V Genentech I Kevin Barr Daiichi Sankyo I Rohit Bishnoi MD Ollie Annum PharmD University of Florida I BHMCR I Leonard Bennett PharmD EMD Serono I Brady Blackman Susmitha Apuri MD MorphoSys I Florida Cancer Specialists I Michael Bennett As of 4-22-21 Kimberly Blandon RN MSN Rick Breitenstein Memorial Cancer Institute I Apellis Pharmaceuticals I Denise Capo Karyopharm Therapeutics I Taryn Boiteau GlaxoSmithKline I Amanda Bridges Florida Society of Clinical Heidi Caravetta Tracy Bonds RN, BSN, Oncology I Exelixis, Inc.
    [Show full text]
  • Tachia Newall Actor
    Tachia Newall Actor Please find a link to Tachia’s showreel here. Agents Ruth Young Associate Agent Phoebe Trousdell ptrousdell@unitedagents.co.uk +44 (0)20 3214 0800 Assistant Lauren Morgan lmorgan@unitedagents.co.uk +44 (0)20 3214 0800 Assistant Alex Campbell acampbell@unitedagents.co.uk +44 (0)20 3214 0800 Phoebe Trousdell ptrousdell@unitedagents.co.uk Roles Television Production Character Director Company LIFE AFTER LIFE Winton John Crowley House Productions SILENT WITNESS SERIES 21 PC Josh Bell Colin Teague BBC FROM DARKNESS DC Salter Dominic Leclerc BBC United Agents | 12-26 Lexington Street London W1F OLE | T +44 (0) 20 3214 0800 | F +44 (0) 20 3214 0801 | E info@unitedagents.co.uk1 Production Character Director Company VERA - SERIES 5 Ben Marek Losey ITV SCOTT AND BAILEY 4 Ethan Simon Delaney Red Productions CASUALTY Stewart Steve Hughes BBC WATERLOO ROAD Bolton Smilie Nigel Douglas Shed Productions CORONATION STREET Tom, Ian Bevitt ITV WATERLOO ROAD SERIES III- Bolton Smilie Various Shed Productions V YOUNG DRACULA Home Economics Matthew Evans BBC Teacher DOCTORS JJ John Yorke BBC CORONATION STREET Kyle Kay Patrick ITV MOVING ON Rickey Illy Hill LA Productions Stage Production Character Director Company LIGHT FALLS Michael Sarah Manchester Royal Frankcom Exchange MOTHER COURAGE Recruiter/Armourer/Clerk/Fur Amy Hodge Royal Exchange AND HER CHILDREN Coat/Yellow 1 SYLVIA Lloyd George/Lord Cromer/Narrator Kate Prince Old Vic LOVE OF THE Emily Louizou Home FIREFLIES SCUTTLERS Joe Wils Wilson Royal Exchange Theatre HAMLET Reynaldo/Priest/Francisco,
    [Show full text]
  • 2012 Financial Markets Preview Living Creatively
    REPRINT FROM JANUARY 2, 2012 BioCentury ™ THE BERNSTEIN REPORT ON BIOBUSINESS Article Reprint • Page 1 of 8 2012 Financial Markets Preview Living creatively By Stacy Lawrence “As the capital markets Viren Mehta of Mehta Partners. “Many Senior Writer companies don’t have any option but to For small, early stage biotech compa- continue to be difficult, raise at lower valuations.” nies, 2012 could be the year of living traditional investors are able He added: “Many companies are not creatively. able to defer any longer. The moment Although public biotechs raised more to extract terms that are comes for many companies when they funds last year than ever before, the vast have to swallow hard and accept painful majority of the money was debt financing more and more onerous.” dilution.” by established companies with marketed products. Thus while the overall numbers Todd Wyche, Brinson Patrick look good and are likely to continue to do Cash on hand so, precommercial companies will have to large and mid-cap companies (see “The Market volatility and macroeconomic get creative with their financings. 1% Effect,” page 2). risk had most buysiders sitting on the Many of these companies avoided rais- In 2011, public biotechs raised $43 sidelines through the back half of 2011. ing money in 2011 because they didn’t billion, easily eclipsing the record $33.1 Bankers are hopeful that this year will be like the valuations, but Wall Streeters say billion in 2000. But debt accounted for more stable, in which case investors might they are now running out of cash. As a 82% of the total dollars raised, compared be willing to support more deal flow dur- result, they will have to use the tricks at to only 19% in 2000 (see “Debt Domi- ing 1H12 (see “Fear Factor,” page 5).
    [Show full text]
  • John Collins Production Designer
    John Collins Production Designer Credits include: BRASSIC Director: Rob Quinn, George Kane Comedy Drama Series Producer: Mags Conway Featuring: Joseph Gilgun, Michelle Keegan, Damien Molony Production Co: Calamity Films / Sky1 FEEL GOOD Director: Ally Pankiw Drama Series Producer: Kelly McGolpin Featuring: Mae Martin, Charlotte Richie, Sophie Thompson Production Co: Objective Fiction / Netflix THE BAY Directors: Robert Quinn, Lee Haven-Jones Crime Thriller Series Producers: Phil Leach, Margaret Conway, Alex Lamb Featuring: Morven Christie, Matthew McNulty, Louis Greatrex Production Co: Tall Story Pictures / ITV GIRLFRIENDS Directors: Kay Mellor, Dominic Leclerc Drama Series Producer: Josh Dynevor Featuring: Miranda Richardson, Phyllis Logan, Zoe Wanamaker Production Co: Rollem Productions / ITV LOVE, LIES AND RECORDS Directors: Dominic Leclerc, Cilla Ware Drama Producer: Yvonne Francas Featuring: Ashley Jensen, Katarina Cas, Kenny Doughty Production Co: Rollem Productions / BBC One LAST TANGO IN HALIFAX Director: Juliet May Drama Series Producer: Karen Lewis Featuring: Sarah Lancashire, Nicola Walker, Derek Jacobi Production Co: Red Production Company / Sky Living PARANOID Directors: Kenny Glenaan, John Duffy Detective Drama Series Producer: Tom Sherry Featuring: Indira Varma, Robert Glennister, Dino Fetscher Production Co: Red Production Company / ITV SILENT WITNESS Directors: Stuart Svassand Mystery Crime Drama Series Producer: Ceri Meryrick Featuring: Emilia Fox, Richard Lintern, David Caves Production Co: BBC One Creative Media Management
    [Show full text]
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • Perrigo Needs Deal to Thwart Mylan
    November 02, 2015 Perrigo needs deal to thwart Mylan Madeleine Armstrong Perrigo continues to resist Mylan’s overtures, but a deal is looking increasingly likely after its attempts to block the buy in court failed. Mylan has until November 13 to tempt Perrigo shareholders under Irish takeover rules. An acquisition of its own might now be the only hope for Perrigo in this buy-or-be-bought saga. But, with increasing consolidation in the speciality pharma space, the pool of potential targets is dwindling (see table below). The best option looks like Endo International, though its market cap of nearly $14bn might make it too big a bite for Perrigo, which has just $5bn in cash. But if Perrigo could pull it off it would gain a company with one of the best forecast growth rates in mid-tier pharma. Jazz Pharmaceuticals, Meda or Lundbeck could be easier to digest but the last, with faltering sales, might not be such an attractive proposition. Perrigo and its potential acquisition targets Company Based Market cap ($bn) 2014 sales ($m) 2020e sales ($m) CAGR Perrigo Ireland 23.1 815 1,388 +9% Endo International US 13.6 2,053 5,616 +18% Jazz Pharmaceuticals Ireland 8.4 1,163 2,151 +11 Lundbeck Denmark 5.9 2,222 1,974 -2% Meda Sweden 5.4 1,963 2,519 +4% Last line of defence Perrigo’s chief executive, Joseph Papa, is standing firm but the company’s share price closed down 5% at $157.74 on Friday, well off its 2015 high of $203.69 in April after Mylan formalised its bid (Mylan anti-chain action as good as confirms Teva interest, April 09, 2015).
    [Show full text]
  • State of Maryland Invitation for Bids
    STATE OF MARYLAND DEPARTMENT OF PUBLIC SAFETY & CORRECTIONAL SERVICES INVITATION FOR BIDS FOR Reflective Validation Sheeting for Maryland Correctional Enterprises eMM No. MDQ003I 042561 ISSUE DATE: 111112019 MINORITY BUSINf,SS f,NTERPRISES ARE ENCOURAGED TO RESPOND TO THIS SOLICITATION NOTICE TO VENDORS In order to help us improve the quality of State solicitations, and to make our procurement process more responsive and business friendly, we ask that you take a few minutes and provide comments and suggestions regarding this solicitation. Please retum your comments with your response. [fyou have chosen not to respond to tlris Contract, please email or fax this completed form to the attention ofthe Procurement Officer (see Key Infonnation Sheet below for contact information). Title: Reflective Validation Sheeting for Maryland Correctional Enterprises Solicitation No: MDQ 003104256f L Ifyou have chosen not to respond to this solicitation, please indicate the reason(s) below: ) Other corr.rmitmemts preclude our participation at this time. ) The subject ofthe solicitation is not something we ordinarily provide. ) We are inexperienced in the work/commodities required. ( ) Specifications are unclear, too restrictive, etc. (Explain in RIMARKS section.) ( ) The scope ofwork is beyond our present capacity. ( ) Doing business with the State of Maryland is simply too complicated. (Explain in REMARKS secuon.) ( ) We cannot be competitive. (Explain in REMARKS section.) ( ) Time allotted for completion of the Bid/proposal is insufficient. ( ) Start-up time is insufficierrt. ( ) Bonding/lnsurance requirements are restrictive. (Explain in REMARKS section.) ( ) BidiProposal requirements (other than specificationsj -e un.eusonable or too risky. (Explain in REMARKS section.) ( ) MBE or VSBE requirements. (Explain in REMARKS section.) ( ) Prior Slate of Maryland contract experience was unprofitable or otherwise unsatisfactory.
    [Show full text]
  • Amgen Inc. V. Sanofi, No
    No. IN THE Supreme Court of the United States ———— AMGEN INC., AMGEN MANUFACTURING LIMITED, AND AMGEN USA, INC., Petitioners, v. SANOFI, AVENTISUB LLC, REGENERON PHARMACEUTICALS INC., AND SANOFI-AVENTIS U.S., LLC, Respondents. ———— On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit ———— PETITION FOR A WRIT OF CERTIORARI ———— STUART L. WATT JEFFREY A. LAMKEN WENDY A. WHITEFORD Counsel of Record ERICA S. OLSON MICHAEL G. PATTILLO, JR. EMILY C. JOHNSON SARAH J. NEWMAN AMGEN INC. MOLOLAMKEN LLP One Amgen Center Drive The Watergate, Suite 660 Thousand Oaks, CA 91320 600 New Hampshire Ave., NW (805) 447-1000 Washington, D.C. 20037 (202) 556-2000 jlamken@mololamken.com Counsel for Petitioners :,/621(3(635,17,1*&2,1&± ±:$6+,1*721'& QUESTION PRESENTED The 1952 Patent Act requires patents to “contain a written description of the invention, and of the manner and process of making and using it.” 35 U.S.C. §112(a). The “written description” must be “in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.” Ibid. “The object of the statute is to require the patentee to describe his invention so that others may construct and use it after the expiration of the patent.” Schriber-Schroth Co. v. Cleveland Tr. Co., 305 U.S. 47, 57 (1938). The Federal Circuit has construed §112(a) as impos- ing separate “written description” and “enablement” re- quirements subject to different standards.
    [Show full text]
  • Corporate Responsibility Report
    Corporate Responsibility Report October 2019 ©2019 Alkermes. All rights reserved. Table of Contents Section 1: Introduction . 2 Section 2: About Our Company . 3 Section 3: Our Approach to Corporate Responsibility . 4 Section 4: Environment . 6 Section 5: Social . 15 Section 6: Governance . 23 Section 7: The Future of Corporate Responsibility at Alkermes and About This Report . 27 ALKERMES • CORPORATE RESPONSIBILITY REPORT 1 SECTION 1 INTRODUCTION A Message from Our CEO Alkermes was founded by pioneers in the field of Inspired by the courage and determination of individuals neuroscience, and their legacy of innovation and in these frequently underserved and marginalized scientific excellence — applied to the real-world needs communities, we are driven to develop medicines and of patients — remains central to our mission. Alkermes contribute to systemic solutions that we hope will have technologies and discoveries have contributed to a meaningful impact on the lives of patients. important medicines that continue to shape the treatment landscape in many disease areas. Today, Our Commitment we are distinguished from other biopharmaceutical As we look toward building our business for the companies by our core focus on serious mental illness future, we are guided by the opportunity — and what and addiction — chronic, highly prevalent conditions we believe is our responsibility — to help address the that affect millions of people and represent some of unmet needs of patients and to operate in a sustainable, the most challenging public health issues of our time. socially responsible manner. We firmly believe that doing so is best for our business, our employees, for Great science. Deep compassion.
    [Show full text]